



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 12 Dec 2018 (#37)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Contact: RGMO Pre-Awards cdevries@sun.ac.za

Important Notices

- [Understanding Age in the NIH Portfolio: Implementation of the NIH Inclusion Across the Lifespan Policy](#)
December 2017, NIH announced a revision to its Inclusion of Children Policy to expand the policy to individuals of all ages ([NOT-OD-18-116](#)). The revised policy, now called the [Inclusion Across the Lifespan policy](#), requires individuals of all ages (including children and older adults) be included in clinical research studies unless there are scientific or ethical reasons to exclude them. For applications submitted for due dates January 25, 2019 or later, NIH will require awardees to submit de-identified participant-level data on sex/gender, race, ethnicity, and age at enrollment in progress reports.
- [What Contributes to the Success of Early Career Scientists? – A NIAID Look](#) NIH is heavily invested in early-career researchers and in understanding the barriers they face. What characteristics do they share? How do they compete in the current hypercompetitive environment? When do they stop applying to NIH (drop out), even after receiving their first award? Staff from the National Institute of Allergy and Infectious Diseases (NIAID) delve into these questions in a paper published recently in [PLOS ONE](#). Survival of junior scientists in academic biomedical research is difficult in today's highly competitive funding climate. NIH data on first-time R01 grantees indicate the rate at which early investigators drop out from a NIH-supported research career is most rapid 4 to 5 years from the first R01 award.
- [Revised NIH Grants Policy Statement for Fiscal Year 2019](#) NIH has released a revised Grants Policy Statement that applies to all NIH grants and cooperative agreements with budget periods beginning on or after 1 October 2018. This revised version does not introduce new policies, but it does incorporate all policy changes or updates made throughout the previous year and includes significant enhancements to improve the user interface, navigation, and search.
- [NIH, Fogarty receive funding increase for Fiscal Year 2019](#) The [NIH budget](#) was approved by Congress and signed into law by President Donald Trump in late September, providing funding for Fiscal Year 2019 just prior to its start 1 October. NIH received a \$2 billion increase over the previous year, bringing its budget to \$39.1 billion. Fogarty's allocation also saw a boost, for a total of \$78.1 million.
- [NIH weighs new opportunities in global health research FIC Director Dr Roger Glass](#) Dr. Glass shares his thoughts on how Fogarty should take advantage of the new frontiers of global health science by using technologies, building data science capacity and leveraging LMIC research infrastructure.
- Apply to participate in the [Training Institute for Dissemination and Implementation Research in Health](#), an online course held February through June 2019, plus a 2-day in-person training 8 & 9 July 2019, in Bethesda, Maryland. **Open to foreign applicants**. No fee to apply or to attend. All applicants are responsible for arranging and paying for their travel. Application deadline: January 16, 2019.
- [mHealth Training Institute](#) 28 July - 2 August 2019. Conducted and hosted by the University of California, Los Angeles, and sponsored in part by NIH. **Foreign applicants are welcome**. There are no registration fees for participants, who also receive accommodations and meals. Application deadline: 27 January 2019

1. Long-acting Drug Delivery Systems for ART Optimization in HIV-1 Infected Children (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(RFA-AI-18-057\)](#)

Type:R61/R33

Application Due Date: March 13, 2019. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to accelerate development of safe and effective long-acting drug delivery systems (LA-DDS) for improved, simplified treatment of HIV-1 in children. This FOA invites applicants engaged in the development of existing LA-DDS platforms at early product development stages to perform specific preclinical activities that enable product optimization and accelerated translation to HIV-1 infected children. Collaborative research partnerships with industry are required.

Budget: NIAID intends to commit \$3.86M in FY 2020 to fund 3-4 awards. Application budgets are limited to \$640,000 in direct costs per year for the R61 award phase and \$860,000 in direct costs per year for the R33 award phase. The total project period for an application submitted in response to this FOA is five years. Applicants may request up to two years of support for the R61 phase, and up to three years of support for the R33 phase.

2. Telomeres in Wellness and Disease: A Biobehavioral Approach (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PA-19-073\)](#)

Type: R21

[\(PA-19-074\)](#)

R01

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research that examines the role of telomeres in wellness and disease, and to advance the incorporation of telomere studies into biobehavioral programs of research. A body of research has demonstrated the contribution of telomeres to health-related outcomes; however, additional studies are needed to achieve the full potential for incorporating telomere-guided approaches for maintaining wellness, reducing the risk and burden of disease, and for advancing symptom and self-management strategies.

Budget: R21 - The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 in direct costs may be requested in any single year. R01 - Application budgets are not limited but need to reflect the actual needs of the proposed project. The total project period for an application submitted in response to this funding opportunity may not exceed 5 years.

3. Engaging Men in HIV Testing, Prevention, and Care (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PA-19-50\)](#)

Type: R21

[\(PA-19-042\)](#)

R01

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to develop and test strategies to increase the engagement of men in HIV prevention and care within global settings and among US domestic populations who have evidenced lower rates of engagement and retention in HIV prevention and care. The R01 mechanism is intended to support a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies. The R21 Exploratory/Developmental Grant supports studies that may involve considerable risk but may lead to a breakthrough in a particular area; or to the development of novel techniques, agents, methodologies, models; or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.

Budget: R21-The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. R01 - Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

4. Exploring Molecular Links Between Dietary Interventions and Circadian Rhythm (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(RFA-AG-19-029\)](#)

Type: R01

Application Due Date: March 6, 2019. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This FOA encourages innovative experimental approaches to explore how dietary intervention entrains peripheral or central clocks to maintain tissue homeostasis and how circadian regulation integrates with various dietary strategies to achieve optimal health benefits.

Budget: NIA intends to commit \$2.5 million in total costs in FY 2019 to fund 4-6 awards. Application budgets are limited to \$250,000 in direct costs per year and need to reflect the actual needs of the proposed project. The scope of the project should determine the project period. The maximum project period is 5 years.

5. Promoting Reductions in Intersectional StigMa (PRISM) to Improve the HIV Prevention Continuum (R34 Clinical Trial Required)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(RFA-MH-19-410\)](#)
[\(RFA-MH-19-411\)](#)
[\(RFA-MH-19-412\)](#)

Type: R34
R21
R01

Application Due Date: January 23, 2019. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) solicits research grant applications which will: 1) advance measurements of intersectional stigma (multiple stigmatized identities) and examine the mechanisms and pathways by which it is a barrier to HIV testing and linkage to prevention; or 2) develop and test interventions to reduce intersectional stigma and improve the uptake of HIV testing and linkage to ongoing HIV prevention among key populations at substantial risk for HIV infection.

RFA-MH-19-412 uses the R01 grant mechanism and RFA-MH-19-411 uses the R21 mechanism, while RFA-MH-19-410 this uses the R34 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism. Applications with preliminary data and/or those including longitudinal analysis should consider using for the R01 mechanism. Applicants proposing to develop and pilot test an intervention should consider the R34 mechanism.

Budget: NIH intends to fund an estimate of 4-6 awards, corresponding to a total of \$2,000,000 in direct costs for fiscal year 2019. R34 - Direct costs are limited to \$450,000 over the R34 project period, with no more than \$225,000 in direct costs allowed in any single year. The scope of the proposed project should determine the project period. The maximum project period is 3 years. R21 - The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. R01 - Direct costs are limited to \$2,499,995 over the entire R01 project period, with no more than \$499,999 in direct costs allowed in any single year. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

6. Accelerating Malaria Vaccine Discovery (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PA-19-077\)](#)

Type: R01

Application Due Date: [Standard dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to support early phase translational research that will generate new malaria vaccine candidates suitable for further downstream development and clinical evaluation. This research opportunity encourages studies that will lead to discovery of new vaccine candidates that prevent infection, ameliorate disease, and/or interrupt transmission caused by human malaria parasites, especially *P. falciparum* and *P. vivax*.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

7. Advancing Development of Rapid Fungal Diagnostics (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PA-19-080\)](#)
[\(PA-19-081\)](#)

Type: R01
R21

Application Due Date: [Standard dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement is to support the development of rapid, sensitive, specific, simple, and cost-effective diagnostics for primary health-care settings (hospitals and point-of-care).

Budget: R01- Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years. R21 - Direct costs are limited to \$275,000 over a two-year project period, with no more than \$200,000 in direct costs allowed in any single year.

8. Novel approaches to understand, prevent, treat, and diagnose coccidioidomycosis (Valley Fever) and other select endemic fungal infections (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PA-19-082\)](#)
[\(PA-19-083\)](#)

Type: R01
R21

Application Due Date: [Standard dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement is to support research activities that will contribute to the overall understanding of coccidioidomycosis, commonly known as Valley Fever, and other select endemic fungal diseases including histoplasmosis and blastomycosis. This research opportunity encourages studies that address diverse scientific areas such as: 1) pathogenesis; 2) host response; 3) disease transmission; 4) natural history and environmental factors contributing to disease; 5) vaccines; 6) diagnostics; and 7) therapeutics; with the ultimate goal of advancing the field towards solutions for the improved detection, prevention and treatment of select endemic mycoses.

Budget: R01- Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years. R21 - Direct costs are limited to \$275,000 over a two-year project period, with no more than \$200,000 in direct costs allowed in any single year.

9. NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PA-19-091\)](#)

Type: R01

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in [NOT-OD-18-212](#) as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate ‘Clinical Trials Required’ or ‘Clinical Trial Optional’ FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. View their respective areas of research interest at the [R01 Basic Experimental Studies with Humans Required IC-Specific Scientific Interests and Contact website](#). ICs that do not participate in this announcement will not consider applications for funding.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

10. NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PA-19-092\)](#)

Type: R21

Application Due Date: [Standard dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in [NOT-OD-18-212](#) as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate ‘Clinical Trials Required’ or ‘Clinical Trial Optional’ FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest at the [R21 Basic Experimental Studies with Humans Required IC-Specific Scientific Interests and Contact website](#). ICs that do not participate in this announcement will not consider applications for funding.

Budget: The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

11. Emotion Regulation, Aging and Mental Disorder (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PA-19-094\)](#)
[\(PA-19-095\)](#)

Type: R01
R21

Application Due Date: [Standard dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) encourages applications for mechanistic research on age-related changes in emotion regulation and how they may contribute to mental disorders in middle-aged and older adults. In particular, research is sought that will advance understanding of irregularities in the integrative neural-behavioral mechanisms of emotion regulation in adult mood and anxiety disorders, and that will examine whether the irregularities are associated with typical or atypical maturational trajectories of emotion processing. Currently, it is not known whether older adults who suffer episodes of affective dysregulation share the same patterns of improved emotional function with age as have been found to be typical of the older adult population in general. Research that helps to clarify whether they do or do not manifest typical emotion processing trajectories may lead to very different understandings of the irregularities involved in their dysregulation. It is anticipated that such studies may identify novel targets for mental health interventions or prevention efforts, or provide clues as to which available intervention strategies might be optimally applied to normalize emotion dysregulation or to strengthen emotional resilience at particular stages of the adult life cycle. PA-19-094 uses the R01 grant mechanism while PA-19-095 uses the R21 mechanism. Investigators proposing high risk/high reward projects, projects that lack preliminary data, or studies that utilize existing data may wish to apply using the R21 mechanism, while applicants with preliminary data may wish to apply using the R01 mechanism.

Budget: R01- Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years. R21 - Direct costs are limited to \$275,000 over a two-year project period, with no more than \$200,000 in direct costs allowed in any single year.

12. Control of Sexually Transmitted Infections (STIs) Through a Comprehensive Understanding of the Natural History of Infection (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PA-19-096\)](#)

Type: R01

Application Due Date: [Standard dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to encourage research to advance the understanding of natural history of infection for three sexually transmitted infections (STIs): gonorrhea, syphilis, and chlamydia. This research opportunity encourages studies that address the natural history of infection in the context of either: 1) correlates of protection, 2) host response to infection, 3) clinical endpoints of disease, or 4) biological and clinical factors that influence clearance rather than persistence of infection.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

13. Molecular and Genetic Characterization of Inborn Errors of Immunity (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PAR-19-078\)](#)

Type: R01

Application Due Date: [Standard dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to advance the experimental validation and functional characterization of genetic variants in coding or non-coding genomic regions that result in inborn errors of immunity/primary immunodeficiency diseases and to elucidate the molecular, cellular, and immunological mechanisms of these disorders. Understanding the genetic basis of primary immunodeficiency disorders is essential for their diagnosis, prognosis, and the development of precision therapeutics.

Budget: R01- Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years. R21 - Direct costs are limited to \$275,000 over a two-year project period, with no more than \$200,000 in direct costs allowed in any single year.

14. Research to Advance HBV Cure: HIV/HBV Co-Infection and HBV Mono-infection (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PAS-19-097\)](#)

Type: R01

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for support of innovative basic, translational, and clinical research to identify and address the challenges to achieving hepatitis B virus (HBV) cure in the presence or absence of human immunodeficiency virus (HIV).

Budget: NIH intends to fund an estimate of 3-5 awards, corresponding to a total of \$4.1M, for fiscal year 2020, 2021, 2022. Future year amounts will depend on annual appropriations. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Brief definitions of some NIH grant mechanisms: [comprehensive list of extramural grant and cooperative agreement activity codes](#)